Product Description
Mechanisms of Action: PPAR-d Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: Europe
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Type 2 Diabetes|Dyslipidemia|Metabolic Syndrome X|Overweight|Hyperglycemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2005-001558-26 |
2005-001558-26 | P2 |
Completed |
Overweight |
2007-06-25 |
2022-03-12 |
Treatments |
|
NCT00196989 |
ADG20001 | P2 |
Completed |
Type 2 Diabetes |
2007-04-01 |
2019-03-21 |
Treatments |
|
NCT00437164 |
ADG106149 | P2 |
Terminated |
Type 2 Diabetes |
2006-11-01 |
2019-03-21 |
Treatments |
|
2006-001275-38 |
2006-001275-38 | P2 |
Terminated |
Hyperglycemia|Type 2 Diabetes |
2006-10-20 |
2022-03-12 |
Patient Enrollment|Treatments |
|
NCT00264667 |
ADG103440 | P2 |
Completed |
Dyslipidemia|Metabolic Syndrome X |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|